BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res 2009;69:5073-81. [PMID: 19491272 DOI: 10.1158/0008-5472.CAN-08-3839] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Che HY, Guo HY, Si XW, You QY, Lou WY. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration. Tumour Biol 2014;35:8659-64. [PMID: 24867098 DOI: 10.1007/s13277-014-2118-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
2 Morrow JK, Du-Cuny L, Chen L, Meuillet EJ, Mash EA, Powis G, Zhang S. Recent development of anticancer therapeutics targeting Akt. Recent Pat Anticancer Drug Discov 2011;6:146-59. [PMID: 21110830 DOI: 10.2174/157489211793980079] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
3 Che HY, Guo HY, Si XW, You QY, Lou WY. Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility. Onco Targets Ther 2014;7:425-32. [PMID: 24665203 DOI: 10.2147/OTT.S57324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
4 Sun C, Zhang M, Shan X, Zhou X, Yang J, Wang Y, Li-Ling J, Deng Y. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol 2010;136:603-10. [PMID: 19816711 DOI: 10.1007/s00432-009-0698-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
5 Xi Y, Chen M, Liu X, Lu Z, Ding Y, Li D. CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration. Onco Targets Ther 2014;7:1215-21. [PMID: 25050066 DOI: 10.2147/OTT.S62946] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
6 Huang PH, Chuang HC, Chou CC, Wang H, Lee SL, Yang HC, Chiu HC, Kapuriya N, Wang D, Kulp SK, Chen CS. Vitamin E facilitates the inactivation of the kinase Akt by the phosphatase PHLPP1. Sci Signal 2013;6:ra19. [PMID: 23512990 DOI: 10.1126/scisignal.2003816] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
7 Kuo MS, Auriau J, Pierre-Eugène C, Issad T. Development of a human breast-cancer derived cell line stably expressing a bioluminescence resonance energy transfer (BRET)-based phosphatidyl inositol-3 phosphate (PIP3) biosensor. PLoS One 2014;9:e92737. [PMID: 24647478 DOI: 10.1371/journal.pone.0092737] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
8 Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos DΑ, Libra M, Tsatsakis AM. Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int J Oncol 2016;48:869-85. [PMID: 26698230 DOI: 10.3892/ijo.2015.3306] [Cited by in Crossref: 186] [Cited by in F6Publishing: 179] [Article Influence: 26.6] [Reference Citation Analysis]
9 Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle RB, Guzman R, Pagel MD, Meuillet EJ. Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer. Int J Nanomedicine 2014;9:5653-65. [PMID: 25516710 DOI: 10.2147/IJN.S68511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
10 Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA. Development of sulfonamide AKT PH domain inhibitors. Bioorg Med Chem 2011;19:2046-54. [PMID: 21353784 DOI: 10.1016/j.bmc.2011.01.049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
11 McNamara CR, Degterev A. Small-molecule inhibitors of the PI3K signaling network. Future Med Chem 2011;3:549-65. [PMID: 21526896 DOI: 10.4155/fmc.11.12] [Cited by in F6Publishing: 75] [Reference Citation Analysis]
12 Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther 2011;12:1032-49. [PMID: 22157148 DOI: 10.4161/cbt.12.12.18442] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
13 Chen L, Du-Cuny L, Moses S, Dumas S, Song Z, Rezaeian AH, Lin HK, Meuillet EJ, Zhang S. Novel inhibitors induce large conformational changes of GAB1 pleckstrin homology domain and kill breast cancer cells. PLoS Comput Biol 2015;11:e1004021. [PMID: 25569504 DOI: 10.1371/journal.pcbi.1004021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
14 Yan R, Chuang HC, Kapuriya N, Chou CC, Lai PT, Chang HW, Yang CN, Kulp SK, Chen CS. Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors. J Med Chem 2015;58:2290-8. [PMID: 25689347 DOI: 10.1021/jm501751b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
15 Yang R, Wang M, Zhang G, Li Y, Wang L, Cui H. POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway. Cell Death Dis 2021;12:433. [PMID: 33931589 DOI: 10.1038/s41419-021-03719-3] [Reference Citation Analysis]
16 Dickinson SE, Janda J, Criswell J, Blohm-Mangone K, Olson ER, Liu Z, Barber C, Petricoin EF 3rd, Calvert VS, Einspahr J, Dickinson JE, Stratton SP, Curiel-Lewandrowski C, Saboda K, Hu C, Bode AM, Dong Z, Alberts DS, Timothy Bowden G. Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. Cancer Prev Res (Phila) 2016;9:215-24. [PMID: 26801880 DOI: 10.1158/1940-6207.CAPR-15-0419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
17 Meuillet EJ. Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain. Curr Med Chem 2011;18:2727-42. [PMID: 21649580 DOI: 10.2174/092986711796011292] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
18 Wiechmann S, Ruprecht B, Siekmann T, Zheng R, Frejno M, Kunold E, Bajaj T, Zolg DP, Sieber SA, Gassen NC, Kuster B. Chemical Phosphoproteomics Sheds New Light on the Targets and Modes of Action of AKT Inhibitors. ACS Chem Biol 2021;16:631-41. [PMID: 33755436 DOI: 10.1021/acschembio.0c00872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
19 Mattmann ME, Stoops SL, Lindsley CW. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin Ther Pat 2011;21:1309-38. [PMID: 21635152 DOI: 10.1517/13543776.2011.587959] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
20 Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther 2010;9:706-17. [PMID: 20197390 DOI: 10.1158/1535-7163.MCT-09-0985] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
21 Kobes JE, Daryaei I, Howison CM, Bontrager JG, Sirianni RW, Meuillet EJ, Pagel MD. Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor. Pancreas 2016;45:1158-66. [PMID: 26918875 DOI: 10.1097/MPA.0000000000000607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
22 Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem 2009;17:6983-92. [PMID: 19734051 DOI: 10.1016/j.bmc.2009.08.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
23 Sheng Z, Ma L, Sun JE, Zhu LJ, Green MR. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 2011;118:2840-8. [PMID: 21715304 DOI: 10.1182/blood-2010-12-322537] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
24 Miao B, Skidan I, Yang J, Lugovskoy A, Reibarkh M, Long K, Brazell T, Durugkar KA, Maki J, Ramana CV, Schaffhausen B, Wagner G, Torchilin V, Yuan J, Degterev A. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci U S A 2010;107:20126-31. [PMID: 21041639 DOI: 10.1073/pnas.1004522107] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 7.3] [Reference Citation Analysis]
25 Yanes-Díaz J, Palao-Suay R, Aguilar MR, Riestra-Ayora JI, Ferruelo-Alonso A, Rojo Del Olmo L, Vázquez-Lasa B, Sanz-Fernández R, Sánchez-Rodríguez C. Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell Carcinoma. Pharmaceutics 2021;13:1242. [PMID: 34452203 DOI: 10.3390/pharmaceutics13081242] [Reference Citation Analysis]